In mice genetically engineered to develop Alzheimer’s-like brain changes, removing microglia with a specific drug increases daily NREM sleep by more than two hours, even though the amount of amyloid plaques in the brain remains unchanged.
See the scientific wording
Microglial depletion via CSF1R inhibitor PLX3397 in APPswe/PSEN1dE9 mice increases non-rapid eye movement (NREM) sleep by more than 2 hours per day without altering amyloid plaque burden, demonstrating that microglial activity influences sleep disruption independently of amyloid pathology.
Correlational — new studies may shift this
ObservationalOne low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Early microglial response to amyloid plaques drives sleep loss in Alzheimer's disease
Cohort StudyAnimal2026
Scientists removed a type of brain cell called microglia from mice with Alzheimer’s-like brain plaques, and those mice slept over 2 extra hours a day — even though the plaques were still there. This means the brain cells, not the plaques, were causing the sleep loss.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
When brain cells called microglia become overactive, they cause abnormal electrical activity in the brain regions that control sleep. This disrupts the coordinated rhythm between the thalamus and cortex, making it harder for the brain to enter and stay in deep sleep. Removing these overactive cells restores normal brain rhythms and increases deep sleep, even if the harmful protein clumps remain unchanged.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In mice genetically engineered to develop Alzheimer’s-like brain changes, removing microglia with a specific drug increases daily NREM sleep by more than two hours, even though the amount of amyloid plaques in the brain remains unchanged.
Mechanism
1 studyOveractive brain immune cells disrupt the rhythm between key sleep regions, making deep sleep unstable. Removing these cells fixes the rhythm and brings back deep sleep, even if the harmful protein clumps are still there. In aging, a similar process in a different brain area reduces REM sleep by slowing brain waves.
When brain cells called microglia become overactive, they cause abnormal electrical activity in the brain regions that control sleep. This disrupts the coordinated rhythm between the thalamus and cortex, making it harder for the brain to enter and stay in deep sleep. Removing these overactive cells restores normal brain rhythms and increases deep sleep, even if the harmful protein clumps remain unchanged.
Amyloid-beta plaques accumulate in cortical and hippocampal regions
Microglia expand and adopt reactive phenotypes in thalamocortical and white matter regions independent of plaque location
Reactive microglia increase pro-inflammatory signaling and induce cortical hyperexcitability, reducing EEG coherence in the theta band
Thalamocortical network desynchronization impairs the generation and consolidation of NREM sleep, reducing delta power and increasing theta power during sleep
Microglial depletion normalizes cortical excitability and restores thalamocortical EEG synchrony, increasing NREM sleep duration and bout length
After microglial repopulation, the sleep-regulatory circuits maintain improved synchrony and reduced inflammation, sustaining elevated NREM sleep
Less supported by current evidence, but not ruled out
In aging, microglia in the thalamus become reactive and cause a shift in brain wave patterns toward slower theta rhythms, which destabilizes transitions between sleep and wake states and reduces REM sleep without affecting deep sleep.
Aging increases disease-associated microglia in the thalamus
Thalamic microglial reactivity increases relative theta power and reduces theta central frequency during wake and NREM sleep
EEG slowing disrupts sleep-wake transitions, reducing REM sleep bout frequency and eliminating sleep rebound after deprivation
Evidence from Studies
Supporting (1)
Community contributions welcome
Early microglial response to amyloid plaques drives sleep loss in Alzheimer's disease
Scientists removed a type of brain cell called microglia from mice with Alzheimer’s-like brain plaques, and those mice slept over 2 extra hours a day — even though the plaques were still there. This means the brain cells, not the plaques, were causing the sleep loss.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of CSF1R Inhibition Effects on Sleep Architecture in Transgenic Alzheimer’s Mouse Models
Systematic review and meta-analysis of all peer-reviewed studies using CSF1R inhibitors in APPswe/PSEN1dE9 or comparable transgenic mice, comparing NREM sleep duration and amyloid plaque load between treated and control groups, with standardized outcome measures and risk of bias assessment.
Double-Blind, Placebo-Controlled Trial of PLX3397 on NREM Sleep and Amyloid Burden in APPswe/PSEN1dE9 Mice
Randomized, double-blind, placebo-controlled study in adult APPswe/PSEN1dE9 mice (n≥30 per group) receiving PLX3397 or vehicle, with polysomnography-measured NREM sleep and quantitative histology for amyloid plaques over 4–8 weeks.
Longitudinal Cohort Study of Microglial Dynamics, NREM Sleep, and Amyloid Accumulation in APPswe/PSEN1dE9 Mice
Prospective longitudinal study tracking individual APPswe/PSEN1dE9 mice from pre-symptomatic to symptomatic stages, with repeated measures of microglial density (via imaging), NREM sleep (via EEG), and amyloid burden (via PET or histology) without intervention.
In Vitro Effects of PLX3397 on Microglial Secretome and Neuronal Sleep-Promoting Signaling in Co-Culture Systems
Co-culture of primary microglia and cortical neurons from APPswe/PSEN1dE9 mice treated with PLX3397 or control, measuring changes in sleep-related signaling molecules and neuronal firing patterns using electrophysiology and ELISA.
Pilot Study of PLX3397 on Sleep and Amyloid in APPswe/PSEN1dE9 Mice with Limited Sample Size
Small-scale (n=5–10 per group) open-label study in APPswe/PSEN1dE9 mice treated with PLX3397, measuring NREM sleep via EEG and amyloid burden via immunohistochemistry, without randomization or blinding.